Adaptimmune Therapeutics plc

NasdaqGS:ADAP Stock Report

Market Cap: US$148.1m

Adaptimmune Therapeutics Management

Management criteria checks 3/4

Adaptimmune Therapeutics' CEO is Ad Rawcliffe, appointed in Sep 2019, has a tenure of 5.25 years. total yearly compensation is $2.77M, comprised of 23.4% salary and 76.6% bonuses, including company stock and options. directly owns 0.1% of the company’s shares, worth $153.85K. The average tenure of the management team and the board of directors is 5 years and 9.8 years respectively.

Key information

Ad Rawcliffe

Chief executive officer

US$2.8m

Total compensation

CEO salary percentage23.4%
CEO tenure5.3yrs
CEO ownership0.1%
Management average tenure5yrs
Board average tenure9.8yrs

Recent management updates

Recent updates

Health Check: How Prudently Does Adaptimmune Therapeutics (NASDAQ:ADAP) Use Debt?

Dec 15
Health Check: How Prudently Does Adaptimmune Therapeutics (NASDAQ:ADAP) Use Debt?

Investors Give Adaptimmune Therapeutics plc (NASDAQ:ADAP) Shares A 32% Hiding

Nov 15
Investors Give Adaptimmune Therapeutics plc (NASDAQ:ADAP) Shares A 32% Hiding

The Market Doesn't Like What It Sees From Adaptimmune Therapeutics plc's (NASDAQ:ADAP) Revenues Yet As Shares Tumble 31%

Sep 26
The Market Doesn't Like What It Sees From Adaptimmune Therapeutics plc's (NASDAQ:ADAP) Revenues Yet As Shares Tumble 31%

Adaptimmune's T-Cell Therapy Journey: A Small Market, Big Ambitions

Sep 12

Adaptimmune: How The Story Is Shaping Up For The Latter Half Of 2024

Jul 03

Adaptimmune: Huge Opportunity Amid Their Setback With Genentech

Apr 26

Benign Growth For Adaptimmune Therapeutics plc (NASDAQ:ADAP) Underpins Stock's 29% Plummet

Apr 16
Benign Growth For Adaptimmune Therapeutics plc (NASDAQ:ADAP) Underpins Stock's 29% Plummet

Adaptimmune Therapeutics plc (NASDAQ:ADAP) Stock Catapults 107% Though Its Price And Business Still Lag The Industry

Feb 22
Adaptimmune Therapeutics plc (NASDAQ:ADAP) Stock Catapults 107% Though Its Price And Business Still Lag The Industry

Adaptimmune: Drug Approval Now Imminent?

Feb 02

Adaptimmune Therapeutics plc's (NASDAQ:ADAP) Share Price Boosted 26% But Its Business Prospects Need A Lift Too

Dec 27
Adaptimmune Therapeutics plc's (NASDAQ:ADAP) Share Price Boosted 26% But Its Business Prospects Need A Lift Too

News Flash: Analysts Just Made A Notable Upgrade To Their Adaptimmune Therapeutics plc (NASDAQ:ADAP) Forecasts

Nov 09
News Flash: Analysts Just Made A Notable Upgrade To Their Adaptimmune Therapeutics plc (NASDAQ:ADAP) Forecasts

New Forecasts: Here's What Analysts Think The Future Holds For Adaptimmune Therapeutics plc (NASDAQ:ADAP)

Mar 08
New Forecasts: Here's What Analysts Think The Future Holds For Adaptimmune Therapeutics plc (NASDAQ:ADAP)

Adaptimmune Therapeutics (NASDAQ:ADAP) Is In A Good Position To Deliver On Growth Plans

Feb 20
Adaptimmune Therapeutics (NASDAQ:ADAP) Is In A Good Position To Deliver On Growth Plans

New Forecasts: Here's What Analysts Think The Future Holds For Adaptimmune Therapeutics plc (NASDAQ:ADAP)

Nov 09
New Forecasts: Here's What Analysts Think The Future Holds For Adaptimmune Therapeutics plc (NASDAQ:ADAP)

Adaptimmune Therapeutics: Depressed Despite Upcoming BLA

Sep 20

We're Interested To See How Adaptimmune Therapeutics (NASDAQ:ADAP) Uses Its Cash Hoard To Grow

Sep 15
We're Interested To See How Adaptimmune Therapeutics (NASDAQ:ADAP) Uses Its Cash Hoard To Grow

Need To Know: The Consensus Just Cut Its Adaptimmune Therapeutics plc (NASDAQ:ADAP) Estimates For 2022

Aug 10
Need To Know: The Consensus Just Cut Its Adaptimmune Therapeutics plc (NASDAQ:ADAP) Estimates For 2022

Gene editing companies benefitting from Roche deal with CAR-T player Poseida Therapeutics

Aug 03

Adaptimmune: Underappreciated Biotech With BLA Filing Q4 Of 2022

Jun 29

Finally Returning To Adaptimmune Therapeutics Ahead Of Anticipated BLA

Jun 19

Adaptimmune Therapeutics: A Little More Patience May Be Profitable

Mar 06

Circling Back On Adaptimmune Therapeutics

Dec 15

We're Keeping An Eye On Adaptimmune Therapeutics' (NASDAQ:ADAP) Cash Burn Rate

Dec 02
We're Keeping An Eye On Adaptimmune Therapeutics' (NASDAQ:ADAP) Cash Burn Rate

Adaptimmune Therapeutics: Diverse Pipeline With Approval Looming

Sep 29

We're Keeping An Eye On Adaptimmune Therapeutics' (NASDAQ:ADAP) Cash Burn Rate

Aug 14
We're Keeping An Eye On Adaptimmune Therapeutics' (NASDAQ:ADAP) Cash Burn Rate

CEO Compensation Analysis

How has Ad Rawcliffe's remuneration changed compared to Adaptimmune Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$45m

Jun 30 2024n/an/a

-US$72m

Mar 31 2024n/an/a

-US$163m

Dec 31 2023US$3mUS$650k

-US$114m

Sep 30 2023n/an/a

-US$95m

Jun 30 2023n/an/a

-US$91m

Mar 31 2023n/an/a

-US$114m

Dec 31 2022US$3mUS$650k

-US$165m

Sep 30 2022n/an/a

-US$175m

Jun 30 2022n/an/a

-US$176m

Mar 31 2022n/an/a

-US$171m

Dec 31 2021US$4mUS$617k

-US$158m

Sep 30 2021n/an/a

-US$156m

Jun 30 2021n/an/a

-US$149m

Mar 31 2021n/an/a

-US$140m

Dec 31 2020US$3mUS$574k

-US$130m

Sep 30 2020n/an/a

-US$123m

Jun 30 2020n/an/a

-US$127m

Mar 31 2020n/an/a

-US$138m

Dec 31 2019US$2mUS$500k

-US$137m

Sep 30 2019n/an/a

-US$144m

Jun 30 2019n/an/a

-US$99m

Mar 31 2019n/an/a

-US$102m

Dec 31 2018US$1mUS$457k

-US$96m

Sep 30 2018n/an/a

-US$87m

Jun 30 2018n/an/a

-US$93m

Mar 31 2018n/an/a

-US$69m

Dec 31 2017US$2mUS$444k

-US$70m

Compensation vs Market: Ad's total compensation ($USD2.77M) is above average for companies of similar size in the US market ($USD653.16K).

Compensation vs Earnings: Ad's compensation has been consistent with company performance over the past year.

CEO

Ad Rawcliffe (52 yo)

5.3yrs

Tenure

US$2,774,041

Compensation

Mr. Adrian G. Rawcliffe, also known as Ad, has been the Chief Executive Officer and Director of Adaptimmune Therapeutics plc since September 1, 2019. He had been the Chief Financial Officer of Adaptimmune...

Leadership Team

NamePositionTenureCompensationOwnership
Adrian G. Rawcliffe
CEO, Principal Accounting Officer & Director5.3yrsUS$2.77m0.10%
$ 153.9k
Helen Tayton-Martin
Co-Founder & Chief Business & Strategy Officerno dataUS$1.18m0.12%
$ 173.7k
Gavin Hilary Wood
Chief Financial Officer4.7yrsUS$1.17m0.0063%
$ 9.3k
William C. Bertrand
COO & Chief Compliance Officer7.8yrsUS$1.22m0.064%
$ 95.0k
Elliot Norry
Chief Medical Officer4.9yrsUS$1.18m0.037%
$ 54.8k
Joanna Brewer
Chief Scientific Officer2.6yrsno data0.0049%
$ 7.2k
Juli Miller
VP of Corporate Affairs & Investor Relationsno datano datano data
Kerry Sharp
Senior VP & General Council9.2yrsno datano data
Dana Lynch
Senior Director of Corporate Communicationsno datano datano data
John Lunger
Chief Patient Supply Officer5.3yrsUS$1.72m0.053%
$ 78.8k
Dennis Williams
Senior Vice President of Late Stage Development5yrsno datano data
Cintia Piccina
Chief Commercial Officerless than a yearUS$2.19m0.015%
$ 22.2k

5.0yrs

Average Tenure

54yo

Average Age

Experienced Management: ADAP's management team is seasoned and experienced (5 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Adrian G. Rawcliffe
CEO, Principal Accounting Officer & Director5.3yrsUS$2.77m0.10%
$ 153.9k
David Mott
Independent Chairman of the Board of Directors9.8yrsUS$174.83k0%
$ 0
Ali Behbahani
Independent Non-Executive Director9.8yrsUS$111.54kno data
Lawrence Alleva
Independent Non-Executive Director9.8yrsUS$128.80k0.0093%
$ 13.8k
Malcolm Brenner
Member of the Scientific Advisory Boardno datano datano data
Wolf Fridman
Member of the Scientific Advisory Boardno datano datano data
John Furey
Independent Non-Executive Director6.4yrsUS$117.25k0%
$ 0
Stephan Grupp
Member of the Scientific Advisory Boardno datano datano data
Michael Dustin
Member of the Scientific Advisory Boardno datano datano data
Thomas Gajewski
Member of the Scientific Advisory Boardno datano datano data
Andy Sewell
Member of the Scientific Advisory Boardno datano datano data
Mario Sznol
Member of the Scientific Advisory Boardno datano datano data

9.8yrs

Average Tenure

59.5yo

Average Age

Experienced Board: ADAP's board of directors are considered experienced (9.8 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 16:37
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Adaptimmune Therapeutics plc is covered by 17 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Peter LawsonBarclays
Ying HuangBofA Global Research
Olga SmolentsevaBryan Garnier & Co